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1. Introduction 
Porphyrins are a unique class of compounds widely present in nature. Due to their distinct 
chemical and photophysical properties they have a variety of applications, the most 
important being presented in Fig. 1.  
Porphyrin chemistry and their applications have undergone a renaissance in the last years 
reflected in the 20 volumes of the recent comprehensive work giving an overview of the 
field (Kadish K.M et al., 2002). Despite the impressive volume of data, the question about 
the actual trends and future involvement of porphyrins in biomedical applications is still a 
hot topic as reflected by the number of publications on photodynamic therapy (Fig.2). 
In the last decades a great deal of efforts from the scientific community focused on 
developing new therapeutic and diagnosis approaches in major diseases, like cancer and 
infection. One of the most dynamic fields of investigation is photodynamic therapy (PDT), 
which takes advantage of controlled oxidative stress for destroying pathogens. 
This article aims at reviewing major topics related to biomedical engineering, porphyrins for 
PDT and photodiagnosis (PDD). We do not intend to provide an exhaustive display and 
comment of the porphyrinoid structures, as a huge number on papers and reviews dealing 
with the subject have already been published. We emphasize herein that porphyrins are also 
among the most promising candidates to be used as fluorescent near infrared (NIR) probes 
for non-invasive diagnosis and this opens the possibility to perform simultaneously tumor 
imaging and treatment in the same approach. It is worth mentioning that, besides their 
medical applications, porphyrins are used in industrial and analytical applications as 
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sensitized solar cells, pigments, in electrocatalysis, as electrodes in fuel cells, and as chemical 
sensors, but these issues are not the subject of this paper. Therefore the present chapter will 
only address the medical applications of porphyrins and metalloporphyrins with a special 
emphasis on photodynamic therapy. 
 
 
Fig. 1. Applications of porphyrins and metalloporphyrins 
 
 
Fig. 2. Ascendant trend of publications on the topic of porphyrins involved in photodynamic 
therapy, as indexed by ISI Web of Knowledge 
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We summarize herein basic concepts in the field, stressing out theoretical and technological 
limitations that currently restrict multidisciplinary research for improving /enlarging 
theoretical and technological approaches in PDT and PDD using porphyrins. Special 
emphasis will be given to the development of novel porphyrinic structures related or 
derived from already confirmed structures and to put them in connection with PDT and 
PDD applications, focusing on symmetrical vs. asymmetrical molecular structures and on 
classical vs. more recent synthetic methods. Dosimetry issues for controlling and 
characterizing related processes, interdisciplinary approaches (chemistry, physics, 
biochemistry and biomedicine) will be also highlighted.  
The major role played by porphyrinoid systems in biomedical applications is due to their 
photochemical (energy and exciton transfer), redox (electron transfer, catalysis) and 
coordination properties (metal and axial ligand binding) and their conformational flexibility 
(functional control) (Senge et al., 2010). The issue of PDT will be extensively adressed in the 
next section, while other medical applications, some of them very recent, will be described 
in section 4.  
2. Photodynamic therapy - main medical application of porphyrins 
PDT typically combines a photosensitizer, molecular oxygen and light to destroy cancer 
cells and microorganisms by oxidative stress (Bonnett R., 2000). Briefly, PDT is based on the 
ability of photosensitisers, including porphyrins, to selectively accumulate and kill tumour 
cells (Dougherty, 1987) by singlet oxygen (1O2) (Berenbaum & Bonnett, 1990), upon guided 
light activation with a particular wavelength (usually via laser endoscopy). Reactive oxygen 
species (ROS) produced by phagocytes underly physiological defense mechanisms against 
microorganisms, which are highly controlled to destroy pathogens, whilst minimally 
affecting the surrounding healthy tissues (Witko-Sarsat et al., 2000). As reviewed by Manda 
et al. (2009) cancer cells show an intrinsic oxidative phenotype, which makes them more 
sensitive to the deleterious action of additional oxidative stress generated for therapeutical 
purposes either by radiotherapy, PDT or even chemotherapy.  
PDT has gained increasing attention in the past decade as a targeted and less invasive 
treatment regimen for a number of medical conditions, spanning from various types of 
cancers and dysplasias to neoangiogenesis, macular degeneration, as well as bacterial 
infections. The advantage is that PDT provides a localized action rather than a systemic one, 
when compared to other cancer therapies which are more harmful to the patient. PDT for 
cancer treatment has been extensively reviewed (Allison & Sibata, 2010; Capella M.A.M. & 
Capella L.S., 2003; Dickson, 2003; Dolmans, 2003; Dougherty, 1998; O’Connor et al., 2009; 
Vrouenraets, 2003; Wilson B.C., 2002). The huge effort in PDT development is highlighted 
by 1074 papers in the field reviewed in PubMed in the last 2 years, while 72 clinical trials in 
PDT were ongoing in March 2011 (http://clinicaltrials.gov). 
2.1 Mechanism of action 
As summarized in Fig. 3, there are two recognized mechanisms of action for PDT. The first 
mechanism (type I) involves light induced excitation of the photosensitizer, promoting an 
electron to a higher energy state. At this point a variety of reactions can take place. For 
example, the photosensitizer in the excited state can act as a reducing agent in the reaction 
to create ROS. Conversely, the excited photosensitizer may act as an oxidizing agent by 
filling the hole vacated by the excited electron. The second mechanism (type II) also 
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involves excitation of the photosensitizer with light, but energy is transferred in this case to 
the triplet ground state of molecular oxygen,  resulting in excited singlet state oxygen which 
is highly cytotoxic (Otsu K et al., 2005). In type I mechanism, oxygen is not always necessary 
for the photodynamic action to take place; however, in type II mechanism, oxygen is 
essential. Differences in the triplet and singlet states reflect ways in which two eectrons can 
be placed in degenerate orbitals and, as such, provide an ideal system to examine processes 
that give rise to Hund's rules for orbital occupancy. Also, the near IR transition between the 
8 triplet and singlet states, at 1270 nm, is not very probable and provides an excellent 
example of selection rules based on changes in spin and orbital angular momentum, 
symmetry, and parity. 
 
 
Fig. 3. Photophysical processes involving porphyrinic sensitizer in the presence of oxygen in 
a modified Jablonski diagram 
The photophysical processes required for photodynamic therapy evidentiate the relevant 
properties for the photosensitizer: wavelength of absorbed light, molar absorbance, 
fluorescent quantum yield, intersystem crossing quantum yield, singlet oxygen quantum 
yield and photobleaching quantum yield. These properties depend on the chemical 
structure of the photosensitizer and will be discussed in paragraph 3.1. 
2.2 PDT, ROS and targeted cell death 
A prominent feature of PDT relies in focusing light and consequent localized 
photoactivation of the sensitizer. This spares normal tissue from the deleterious action of 
ROS generated during PDT reactions. Moreover, selective accumulation of sensitizer in 
tumors was demonstrated, which relies in physiological differences between tumors and 
normal tissues; among them can be cited: tumors have a larger interstitial volume than 
normal tissues, often contain a larger fraction of phagocytes,  contain a large amount of 
newly synthesized collagen, have a leaky microvasculature and poor lymphatic drainage. 
Additionally, the extracellular pH is low in tumors.  Generally cationic sensitizers localize in 
both the nucleus and mitochondria, lipophilic ones tend to stick to membrane structures, 
and water-soluble drugs are often found in lysosomes. Not only the lipid/water partition 
coefficient is important but also other factors such as molecular weight and charge 
distribution (linked to symmetry/asymmetry of the photosensitizer structure). In some 
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cases, light exposure leads to a relocalization of the sensitizers (Moan & Berg, 1992; Moan & 
Peng, 2003; Spikes, 1989). 
Singlet oxygen is a highly reactive ROS that interacts with proteins, nucleic acids and lipids. 
Singlet oxygen has a short lifetime within the cell and can migrate in tissues less than 20 nm 
after its formation. Therefore, the induced injury by singlet oxygen action is highly 
localized. Nevertheless, generation of about 9 x 108 molecules of singlet oxygen per tumor 
cell significantly reduces the cell surviving fraction (Dysart et al., 2005).  
PDT leads to a molecular interplay between cell death pathways, balancing between 
apoptosis, necrosis and autophagy (Dewaele et al., 2010). Generally, photosensitizers which 
specifically target mitochondria  induce ROS-mediated cell death by apoptosis (Oleinick et 
al., 2002), while autophagy occurs during PDT protocols involving sensitizers that localize 
to the endoplasmic reticulum (ER) (Buytaert, 2006; Kessel, 2006). Nonetheless, Pavani et al. 
(2009) demonstrated that photodynamic efficiency is directly proportional to membrane 
binding and is not totally related to mitochondrial accumulation. The presence of zinc in the 
photosensitizer decreases mitochondrial binding and increases membrane interactions, 
leading to improved PDT efficiency. 
Recent evidence points out that mitochondria and ER associated with B-cell lymphoma 2 are 
among the cellular targets damaged in PDT protocols, impacting both apoptosis and 
autophagy. Autophagy may function as a prosurvival or a death pathway in PDT. The 
former function is obvious at low-dose PDT conditions, whereas the latter one contributes to 
the killing of cells exhibiting a phenotype that precludes the development of an apoptotic 
response, or of those cells that surviving to the initial wave of apoptosis after high-dose PDT 
(Kessel 2007; Pattingree, 2005). Apoptosis dominates as a mechanism of cell death in those 
cells having a fully competent apoptotic machinery, whereas autophagy seems to be 
responsible for cell death when apoptosis is compromised (Xue et al., 2007). 
ROS are biologically multifaceted molecules, despite their simple chemical structure. 
Depending on the magnitude and profile of ROS generation in biological systems, on 
cellular location and on the redox balance, ROS can elicit cell death or cell proliferation. On 
one hand, aerobic organisms adapted themselves to the injurious oxidative attack and even 
learned how to use ROS in their own favor, as signaling molecules. On the other hand, ROS 
proved to be powerful weapons in fighting against infection or as therapeutic armentarium 
exploiting oxidative stress. Radiotherapy is one of the clearest examples of anti-cancer 
treatment, whose mechanism relies primarily on ROS, combining the properties of an 
extremely efficient DNA-damaging agent with high spatial focusing on tumor. 
Radiotherapy limitation derives mainly from the carcinogenic potential of the ionizing 
radiation and from the deleterious side-effect associated with the inflammatory response 
triggered by necrosis. Radiation memory underlies long-lasting effects of radiotherapy in 
tumors, but also contributes to persistent damage and dysfunctions of bystander normal 
cells. Taking also advantage of ROS cytotoxic potential, but with significantly less side-
effects than radiotherapy, PDT is a fascinating example of biomedical engineering, 
combining and targeting towards diseased tisssues a photosensitizer, light and oxygen. It is 
an interdisciplinary approach involving chemistry, physics, biology and medicine for 
synergizing and fine-tuning all the three above mentioned components towards an efficient 
and highly targeted treatment regimen. 
Although other classes of molecules have been tested and used as photosensitizers, 
porphyrins and porphyrin-like structures are undoubtly the most relevant for biomedical 
applications. Porphyrins and porphyrin-like structures have long been of interest for PDT 
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due to their low intrinsic toxicity, the ability to accumulate into tumors and to generate 
highly ROS only when photoactivated at convenient wavelengths, adequate for deep tissue 
penetration.  
2.3 PDT in oncology 
It is now obvious that PDT can work as well as surgery or radiation therapy in treating 
certain kinds of cancers and dysplasias, having clear advantages over these treatment 
approaches: no long-term side effects when properly used, less invasive than surgery, can be 
targeted more precisely, can be repeated many times at the same site, if needed, and finally 
it is often less expensive than other cancer treatments. 
The evidence in the published peer-reviewed scientific literature (Awan, 2006; Fayter, 2010; 
Rees, 2010) supports PDT as a safe and effective treatment option for selected patients with 
Barrett’s esophagus, esophageal cancer, and non-small cell lung cancer. Although PDT has 
been proposed for the treatment of various other types of cancers (e.g., head and neck, 
cholangiocarcinoma, prostate), there is still insufficient evidence in the form of well-
designed large, randomized controlled trials. PDT is also successful in the treatment of 
actinic keratoses, Bowen's disease and basal cell carcinoma. 
PDT limitations are mainly related to drug and light accessibility. Although the 
photosensitizer travels throughout the body, PDT only works at the area exposed to light. 
This is why PDT cannot be used to treat leukemias and metastasis. Also, PDT leaves patients 
very sensitive to light, therefore special precautions must be taken after photosensitizers are 
used. PDT cannot be used in people who have acute intermittent porphyria or people who are 
allergic to porphyrins.  
More aggressive local therapies are often necessary to eradicate unresectable tumor cells 
that invade adjacent normal tissue (i.e., malignant glioma), and this might be achieved by 
combining PDT and boron neutron capture therapy (BNCT) (Barth et al., 2005). Both are 
bimodal therapies, the individual components being non-toxic, but tumoricidal in 
combination. Boronated porphyrins are promising dual sensitizers for both PDT and BNCT, 
showing  tumor affinity by the porphyrin ring, ease of synthesis with a high boron content, 
low cytotoxicity in dark conditions, strong light absorption in the visible and NIR regions, 
ability to generate singlet oxygen upon light activation and also ability to display 
fluorescence (Vicente et al., 2010). Several boronated porphyrins have been synthesized and 
evaluated in cellular and animal studies (Renner, 2006; Vicente, 2010).  
Besides more precise photosensitizer targeting, either by specific cellular function-sensitive 
linkages or via conjugation to macromolecules (Verma S. et al., 2007), recent approaches aim 
to combine PDT and a second treatment regimen to either increase the susceptibility  
of tumor cells to PDT or to mitigate molecular responses triggered by PDT. As an example, 
Anand et al. (2009) demonstrated both in vitro and in vivo that low, non-toxic doses  
of methotrexate can significantly and selectively enhance PDT with aminolevulinic acid  
in skin cancers. Banerjee et al (2001) showed that meso-substituted porphyrins could  
impact directly in the radiotherapy outcome, when labeled with beta(-) emitters like 
186/188Re. 
2.4 PDT and immunomodulation 
In contrast with systemic chemo- or radiotherapy, PDT is a local treatment in which the 
treated tumor remains in situ, while the immune response is only locally affected and has 
the capability to recover by recruitment of circulating immune cells. 
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Generally, immune cells are found in the tumor stroma, separated from tumor cells by 
extracellular matrix and basal membrane-like structures which hinder the development of 
an efficient anti-tumor immune response. By destroying the structure of the tumor, PDT 
facilitates direct interaction between immune and tumor cells, resulting in a local or 
systemic immune response, as shown in both preclinical as well as clinical settings 
(Gollnick, 2002). Nonetheless, the efficiency of the in situ vaccination triggered by PDT is 
still debatable (van Duijnhoven et al., 2003). 
As reviewed by Garg et al (2010), PDT is capable of eliciting various effects in the tumor 
microenvironment thereby affecting tumor-associated immune cells and the activation of 
different immune reactions e.g. acute-phase response, complement cascade and production 
of cytokines/chemokines (Garg et al., 2010). The ability of PDT to induce exposure/release 
of certain damage-associated molecular patterns (DAMPs) like HSP70, opens new 
perspectives in PDT and PDT-like photoimmunotherapy (Garg et al., 2010).  
PDT, by evoking oxidative stress at specific subcellular sites through light-activation of 
organelle-associated photosensitizers, may be unique in combining tumor cells destruction 
and antitumor immune response in one therapeutic paradigm (Garg et al., 2011). 
2.5 Antimicrobial PDT 
The very success of antibiotics limited their efficiency by rendering microorganisms 
resistant (Hancock R.E.W., 2007). PDT seems to be a viable alternative, proving to be 
efficient against bacteria (including drug-resistant strains), yeasts, viruses and protozoa. In 
addition to destroying microorganisms, PDT can induce immune stimulatory reactions 
(Castano et al., 2006; Hryhorenko et al., 1998), and consequently has the potential to improve 
the overall host response to infections. 
The positive charge of photosensitizers appears to promote a tight electrostatic interaction 
with negatively charged sites at the outer surface of any species of bacterial cells (Maisch et 
al., 2004). Moreover, drug-resistant microorganisms are as susceptible to PDT as their native 
counterparts (Maisch, 2009), or even more susceptible (Tang et al., 2009). It is considered less 
likely that the bacteria will develop resistance towards PDT (Jori & Coppellotti, 2007; 
Konopka & Goslinski, 2008), presumably because of the short-lived ROS produced by the 
photodynamic effect and the non-specific nature of the photooxidative damage that leads to 
cell death. 
It is known that gram-positive bacteria species are much more sensitive to photodynamic 
inactivation than gram-negative species (Merchat et al., 1996). Efforts have therefore been 
made to design photosensitizers capable of attacking gram-negative strains. This can be 
achieved if photosensitizers are coadministrated with outer membrane disrupting agents 
such as calcium chloride, EDTA or polymixin B nonapeptide, that are able to promote 
electrostatic repulsion and consequent alteration of the cell wall structure. 
As reviewed by Alves et al. (2009), porphyrins can be transformed into cationic entities 
through the insertion of positively charged substituents in the peripheral positions of the 
tetrapyrrole macrocycle, which affect the kinetics and extent of binding to microorganisms. 
The hydrophobicity of porphyrins can be modulated by the number of cationic moieties (up 
to four in meso-substituted porphyrins) or by the introduction of hydrocarbon chains of 
different length on the amino nitrogens.  
Antimicrobial PDT is making rapid advances towards clinical applications in oral infections, 
periodontal diseases, healing of infected wounds and treatment of Acne vulgaris. The first 
product to be applied in the oral cavity came on the market in Canada in 2005 (Periowave™, 
www.intechopen.com
 
Biomedical Engineering – From Theory to Applications 
 
362 
Ondine) and several products for the treatment of infected wounds are under clinical trial. 
Antimicrobial PDT requires topical applications of the photosensitizers, selective for the 
microorganism, without causing significant damage to the host tissue. The possibility of 
adverse effects on host tissues has often been raised as a limitation of antimicrobial PDT. 
However, studies have shown that the photosensitizers are more toxic against microbial 
species than against mammalian cells, and that the concentration of photosensitizer and 
light energy dose necessary to kill the infecting organism has little effect on adjacent host 
tissues.  
Photoactivated disinfection of blood samples and surfaces like benches and floors is also 
introduced as a promising application of antimicrobial PDT. The group of Parsons (2009) 
developed a method for concentrating PDT effect at a material surface to prevent bacterial 
colonization by attaching a porphyrin photosensitizer at, or near to that surface. Anionic 
hydrogel copolymers were shown to permanently bind a cationic porphyrin through 
electrostatic interactions as a thin surface layer. The mechanical and thermal properties of 
the materials showed that the porphyrin acts as a surface cross-linking agent, and renders 
surfaces more hydrophilic. Importantly, Staphylococcus epidermidis adherence was reduced 
by up to 99% relative to the control in intense light conditions and 92% in the dark. As such, 
candidate anti-infective hydrogel-based intraocular lens materials were developed for 
improving patient outcomes in cataract surgery.  
3. Porphyrins as PDT photosensitizers 
Porphyrins are involved as sensitizers in PDT because of their ability to localize in tumors 
and of their capacity to be activated by irradiation (see Fig 3).  
The main basic architectures of the porphyrinoid compounds used as photosensitizers are 
presented in Fig. 4 highlighting the minor differences between them. Porphyrins and 
porphyrin-related dyes used in PDT may have substituents in the peripheral positions of the 
pyrrole rings or on the four methine carbons (meso-positions). 
 
 
 Dihydroporphyrin Tetrahydroporphyrin  Porphyrin 
  (Bacteriochlorin)  (Chlorin) 
Fig. 4. Basic architectures of porphyrinoid photosensitizers 
These derivatives are synthesized to influence the water/lipid solubility, amphiphilicity, 
pKa and stability of the compounds since these parameters determine their 
pharmacokinetics. 
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Porphyrins can also coordinate metal ions by replacing the hydrogen atoms on nitrogen; the 
metal ion and its electronic properties are of importance for their photocytotoxic potential as 
photosensitisers. Several metallophotosensitizers have been developed for clinical purposes. 
Although in most cases, they have lower quantum yields for cell inactivation than they 
would have in the absence of metal ions, they have other properties like improved solubility 
and stability, which makes them interesting as therapeutic substances. The metals used 
include Zn, Pd, Sn, Ru, Pt and Al. 
3.1 Properties of porphyrins relevant for their biomedical applications 
The use of porphyrins in biomedical applications including PDT is tightly connected to their 
physical – chemical characteristics. Among these, most important are their electronic 
molecular absorption and emission properties, but solubility and stability must also be 
taken into account. 
3.1.1 Absorption properties 
Porphyrinoids have a large range of absorption wavelengths together with a large range of 
molar absorbtion coefficients as shown in Fig. 5. Although the absorption of porphyrins 
does not cover the entire PDT window, they compensate that with their ability to localize in 
tumors and their chemical versatility. 
 
 
Fig. 5. Chart of one exclusive pair criteria for photosensitizers suitable for PDT: absorption 
maxima vs. intensity () 
The electronic absorption spectrum of the free-base porphyrins is dominated by a typical 
intense Soret band and four weaker Q bands, located in the spectral range 415-650 nm, 
which are monotonously decreasing in intensity (Kadish et al., 2002). The Q bands of the 
free base porphyrins consist of four absorption peaks which are typical to the Qx(0,0), 
Qx(0,1), Qy(0,0), Qy(0,1) transitions in the free base porphyrin (D2h symmetry). Upon 
complexation with a metal ion, the number of Q bands decreases due to the enhancement of 
the molecular symmetry from D2h to D4h (Boscencu et al., 2008; Boscencu et al., 2010). The 
molecular electronic absorption spectra are usually used for the quantitative determination 
of compounds, but in the case of porphyrinic compounds they give real “fingerprints” that 
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can be used to predict the usefulness of a certain compound as photosensitizer. This is 
explained by the fact that the peripheral substitution does not significantly disturb the inner 
π electron ring of the porphyrinic macrocycle, which is responsible for the active electronic 
transitions in the above mentioned spectral range. 
3.1.2 Emission properties 
Photodetection for tissue characterization in cancer is not new, the first study being reported 
by Policard in 1924, who noticed the fluorescence of a tumor under illumination with UV 
light. This fluorescence was considered to originates from tumor’s endogenous porphyrins 
(Masilamani et al., 2004). Some of the most important aspects of metaloporphyrins are 
connected to the photophysical characteristics of porphyrins in different media: fluorescence 
quantum yields (Φf) and fluorescence lifetimes (τf ).  
Fluorescence emission characteristics of porphyrinic compounds are also important features 
for the biomedical use of porphyrins. In case of their use in photodiagnosis, emission 
characteristics as fluorescence quantum yields and/or fluorescence lifetimes are of 
importance to differentiate the signal of the fluorescent marker from the fluorescence of the 
environmental matter. In case of PDT, all deactivation processes (fluorescence, 
phosphorescence, internal conversion, collisional quenching) play an important role in the 
very process of ROS generation (Fig. 3). 
Despite significant advantages, the porphyrinic compounds as photosensitizers have 
limitations. Due to the large  conjugate systems, they easily form aggregates, which have a 
significantly lower ability to form reactive oxygen species and consequently decrease the 
photodynamic activity. In recent years, nanostructured materials such as liposomes, 
nanoparticles and micelles have been considered as potential carriers for porphyrinic 
compounds that may resolve the aforementioned problems. The presence of polar 
headgroups and hydrophobic chains in micellar structures allows the study of the potential 
affinity of a porphyrinic structure to cell-membrane type structures. 
3.2 Main features for an efficient photosensitizer 
There is a great deal of interest in design and synthesis of new photosenzitizers  
with porphyrinoid structures, with improved characteristics that make worth their 
investigation as possible new PDT drugs. The general characteristics of a good sensitizer, 
displayed as basic requirements, are presented in Table 1. For photosensitizers designed to 
kill cancer or other mammalian cells, it has been found that their intracellular localization is 
another important parameter. For example, the photosensitizers which localize in 
mitochondria seem to be more powerful in killing cells than those locating in lysosomes 
(Mroz et al., 2009). 
Porphyrins are essential constituents of important biological systems. The porphyrin-type 
nucleus, along with metal ions, is found in cytochromes, peroxidases and catalases. Other 
biologically important porphyrins that occur in nature and in the human body are hemin 
(an iron porphyrin - the prosthetic group of hemoglobin and myoglobin), chlorophyll 
(magnesium porphyrin-like compound involved in plant photosynthesis), and vitamin B12 
(cobalt porphyrin-like compound, commonly known as cobalamine). As a result of their 
vital role in biologic processes, metallo-porphyrins have always attracted chemist’s 
attention. Porphyrins proved to be valuable photosensitizers since they are non-toxic, are 
selectively retained in tumors, are cleared in a reasonable time from the body and skin, and 
thus photosensitive reactions are minimized. Moreover, porphyrins have got convenient 
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amphiphilicity which renders them more photodynamically active than symmetrically 
hydrophobic or hydrophilic molecules. 
 
Required features Details 
Purity 
Substance of known composition, stable at room 
temperature 
Toxicity, overdosage, and side 
effects 
- Minimal toxicity in the absence of light 
- Cytotoxic in the presence of light of defined 
wavelength  
- Non- toxic metabolites;  
- Minimal side effects 
Absorption, distribution, 
metabolism and excretion (ADME)
Optimum ADME properties 
Activation and wavelength 
Activation in the phototherapeutical window (600 to 
850 nm) 
Singlet oxygen  
quantum yield 
High singlet oxygen generation quantum yield () 
Cost and availability 
Inexpensive  
Commercially available to allow extensive utilization 
Selectivity 
- Good tumour/healthy tissue localization ratio 
- Favourable subcellular localization to induce an 
apoptotic rather than a necrotic mode of cell death 
Mutagenicity/ 
Carcinogenicity 
Non-mutagenic 
Non-carcinogenic 
Painless 
No pain during the procedure or in the following 
treatment stages  
Combined treatment 
No adverse interactions with other drugs or medical 
procedures 
Multisession 
Possibility for application in repeated sessions, 
without immunosuppressive effects 
Carriers Possibile formulation with different carriers 
Multivalency 
Marker 
and molecular beacon 
Multiple effects desired (antitumoral and 
antimicrobial, antitumor and diagnosis)  
Marker or beacon 
Upgradable chemical structures 
The structure can be easily improved by simple 
chemical reactions 
Table 1. Required features for an efficient photosensitizer  
3.3 Timeline in the development of porphyrinoid photosensitizers 
Porphyrins were identified in the mid-nineteenth century, but it was not until the early 
twentieth century that they were used in medicine. 
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Fig. 6. General frame of the porphyrin type structures involved in biomedical studies  
Porphyrinoid photosensitizers are classified as belonging to the first, second or third 
generation of photosensitizers as shown in Figure 6, or depending on the platform to which 
they belong (porphyrin, chlorophyll, dyes) (Allison R.R. et al., 2004). They could also be 
classified according to their primary mechanism of action and/or according to their use 
(type of cancer, photodiagnosis or therapy). 
The first generation of photosensitizers consists only of hematoporphyrin derivatives and 
was developed during the 70’s. Photosensitizers belonging to the second generation are 
porphyrin derivatives or synthetics made from the late ‘80s on. Second generation 10 
photosensitizers are improved compared to the first generation: they have a definite 
structure (which means they are no more a combination of monomers, dimers and 
oligomers), absorb light at longer wavelengths and cause less skin photosensitization. 
Third generation photosensitizers use available drugs and then modify them with different 
carriers in order to obtain tailored  characteristics.  
Examples of clinically available porphyrin sensitizers are presented in Table 2. 
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Brand names Substance (structure)
Substance
Name 
(abbreviation) 
Substance chemical 
name 
Activation 
wavelengt
h (nm)
Manufacturer 
Photofrin HpD Hematoporphyrin 630 
Axcan Pharma, 
Inc. 
Levulan OHNH
2
O
O
ALA 
5-Aminolevulinic 
acid 630 
DUSA 
Pharmaceuticals
, Inc. 
Metvix 
Metvixia ONH2
O
O
M-ALA Methyl-5-
Aminolevulinic acid
634 
PhotoCure ASA 
Galderma, 
Dallas, TX 
Visudyne 
O
O
NH
N
NH
N
OH
O
O
O
O
O
Verteporfin  690 
Novartis 
Pharmaceuticals 
Foscan Temoporfin 
5,10,15,20-tetrakis (3-
hydroxyphenyl)-
chlorin 
652 
Biolitec Pharma 
Ltd. 
LS11 
NPe6 
Laserphyrin 
OH
N
H
N
N
NH
N
H
OH
O
O
O
O
O
OH
Talaporfin 
mono-L-aspartyl 
chlorine e6 
664 Light Science 
Photochlor 
OH
O
NH
N
H
N
N
O
O
HPPH 
2-(1-Hexyloxyethyl)
-2-devinyl 
pyropheophorbide-a
665 RPCI 
Table 2. Clinically available porphyrin sensitizers (adapted from Allison et al., 2004)  
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Photofrin® (HpD) has the longest clinical history and patient track record being the first 
commercial photosensitiser. It is actually a combination of monomers, dimers, and 
oligomers derived from chemical manipulation of hematoporphyrin (HpD). The complex 
mixture is required for clinical activity. In the US, Photofrin® is FDA approved for early and 
late endobronchial lesions as well as Barrett’s esophagus and esophageal obstructing 
lesions. The drug is approved worldwide for a number of additional uses, such as for 
treatment of bladder cancer. 
5-Aminolevulinic acid (ALA) is a prodrug, a naturally occurring amino acid which is 
converted enzymatically to protoporphyrin. By topical administration the treatment can be 
selectively performed without associated light sensitization of the untreated regions. 
Systemic administration does not have this built in selectivity. The drug is active at 630 nm, 
which should give adequate depth penetration; however, when topically administered, the 
drug has a limited penetration capacity and therefore is less efficient for treating deep 
 
 
First generation 
photosensitizers 
Second generation photosensitizers 
Porphyrin 
sensitizer 
molecular 
structure 
 
Porphyrin 
sensitizer name 
Photofrin Tookad Foscan 
Absorption 
(nm) 
630 763 652 
Localization 
Golgi apparatus 
plasma membrane 
Vasculature 
Endoplasmic reticulum 
(ER) 
Mitochondria 
Primary 
mechanism of 
action 
Vascular damage 
ischemic tumor cell necrosis 
Vascular damage 
Direct tumor cytotoxicity 
Vascular damage 
Most commonly 
light time 
irradiation 
interval 
24-48 h 15 min 96 h 
Status: Approved Clinical trials Approved 
Applications 
Esophageal cancer, lung 
cancer, gastric cancer, cervical 
dysplasia and cancer 
Prostate cancer Head and Neck cancer 
Local side 
effects 
Mild to moderate erythema - 
Swelling, bleeding, 
ulceration scarring 
Systemic side 
effects 
Photosensitivity, mild 
constipation 
- - 
Table 3. Examples of porphyrin sensitizers and their characteristics (adapted from  
O’Connor et al., 2009) 
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lesions. ALA is not highly active, so relatively high light doses or long time treatments are 
needed. Despite using topical anesthetics, ALA PDT can be painful. ALA has been 
successful for esophageal treatment and with the oral form of drug this is convenient. 
Dysplastic epithelium can be reliably destroyed by ALA PDT. 
The methylated form of ALA (M-ALA), known commercially as Metvix®  in Europe and 
Metvixia® in the US, has FDA approval for the treatment of non-hyperkeratotic actinic 
keratoses of the face and scalp, using a red-light source. Metvix also has EU approval for the 
treatment of superficial basal cell carcinomas. Both ALA and its methylated form proved 
clinical efficacy in the treatment of actinic keratoses and have also been used for 
photorejuvenation and inflammatory acne vulgaris. 
Verteporfin, known commercially as Visudyne, is a benzoporphyrin derivative, which is 
clinically active when formulated with liposomes. The photosensitizer is active at 690 nm, 
allowing deep tissue penetration and light activation. The drug is rapidly accumulated and 
cleared, so that skin photosensitization is minimal. Most of the clinical response induced by 
Verteporfin is based on vascular disruption and therefore, this drug seems ideal for lesions 
depending on neovasculature.Verteporfin has been successful as treatment for choroidal 
neovascularization due to serous chorioretinopathy.  
Table 3 presents some of the clinically available sensitizers together with their most relevant 
features in order to emphasize the influence of the chemical changes (among others, free 
base versus metallated form) on the characteristics and applications. 
3.4 Selected aspects of the synthesis 
Synthesis of porphyrins has been extensively reviewed in literature (Kadish K., 2002). 
The hematoporphyrin derivatives (HpD) were the start line for the porphyrinic 
photosensitizers, the result consisting in several commercial products, as Photofrin®, which 
is a mixture of oligomers formed by ether and ester linkages of several porphyrin units, 
delivered as sodium porphimer. Their efficacy is linked also to the different proportions of 
monomers, dimers and oligomers (Mironov et al., 1990). The porphyrinic ring is β-pyrrolic 
substituted in this case. By changing the substitution on the meso positions, new 
photosensitizers can be generated, such as the tetraphenylsulphonated structures (TSPP or 
TSPP4-meso-tetrakis(4-sulfonatophenyl)porphyrin). Despite a few advantages, as solubility 
and low cost, the neurotoxicity, cytoskeletal abnormalities and nerve fiber degeneration in 
systemic administration, has oriented the compound only to topical use (Lapes M. et al., 
1996; Winkelman J.W. et al., 1987). 
Meso-substituted porphyrins (Fig. 7) are more attractive compared to the naturally 
occurring beta substituted porphyrins for different applications including the biomedical 
field. Their synthesis is an ongoing subject of research (Halime Z. et al., 2006; Senge M.O., 
2010, 2005; Lindsey J.S. 2010) being directed toward increasing efficacy in obtaining 
unsymmetric ABCD substituted structures, in larger quantities. One approach is the use of 
microwave (MW) irradiation which offers excellent yields within minutes.  
As shown in figure 7, the porphyrin ring can be substituted in its 5, 10, 15 and 20 positions 
respectively with R1, R2, R3 and R4. If the substituents are all hydrogen atoms, the structure 
is a symmetrical porphin; if the substituents are not hydrogens, but are identical to each 
other, the structure is a symmetrical meso porphyrin. Whenever one or more of R1 to R4 is 
not hydrogen, the structure is an unsymmetrical porphyrin. Porphyrins are said to have 
type A unsymmetrical structure when only R1 is not hydrogen; type A,B – 5, 10 or type  
A,B –  5, 15 when either R1 and R2 or R1 and R3 are not hydrogens; type ABC if only R4 is 
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hydrogen and type ABDC when none of the substituents is hydrogen. Whenever 
unsymmetrical, porphyrins posses an amphiphilic character. 
 
 
Fig. 7. Substitution patterns for porphyrins 
The quest for viable structures, able to compete with Foscan (also known as Temoporfin, see 
Table 2), has included as spearhead the meso- substituted amphiphilic porphyrins.  
The desirable hydrophilic configurations give short singlet oxygen lifetime, unsuitable to 
PDT (Bonnett R., 2000). Controlled equilibrium in terms of hydrophilic-hydrophobic 
character was obtained in structures where porphyrinic periphery was mainly achieved by 
synthesizing a large number of asymmetrical structures, with all Rx (1 to 4) different (i.e.,  
an ABCD unsymmetrical structure) (Rao et al., 2000; Wiehe  et al., 2005). For increased 
targeted delivery and enhancement of phototoxicity by raising the level of the accumulation 
in pathologic cells, several carboplatin-containing porphyrins were synthesized (Brunner et 
al., 2004).  
New structures were synthesized by several methods. The conjugation approach, coupled 
with photophysical studies and biological evaluation was reported for several compounds, 
from folic acid (Schneider et al., 2005) to Pt(II)-containing structures (Song et al., 2002).  
The posibility to add functional groups to the substituted porphyrin recommends this type 
of compounds for multiple biomedical purposes.  
3.4.1 Classical synthesis 
Since the 20’s, with the work  of Nobel laureates H.Fischer and R. Willstätter on porphyrins 
as haemoglobin, chlorophyll and other pigments, followed later by R.B Woodward and A. 
Eschenmoser with the synthesis of vitamin B12, considered at the time as impossible, 
porphyrin synthesis has been continuously leading to complex structures. The Rothemund 
process is considered as classical (Rothemund, 1936, 1939) with the contributions of Adler - 
Longo (Longo, 1969; Adler, 1976) and those of Lindsey (Lindsey, 1986, 1987).  
Some of the complex porphyrinic structures were obtained by adding various substituents 
in all peripheral positions (Fig. 4), others by expanding the core- beginning with five pyrrole 
units: sapphyrin (Chmielewski et al., 1995) and smaragdyirin (Sessler et al., 1998) to the 
turcasarin (Sessler et al., 1994) as relevant extreme examples.  
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The general synthetic methods for meso-porphyrins are presented in Figure 8. 
 
 
Fig. 8. Theoretical synthetic approach for the peripheral substitution on meso- porphyrins 
Four pathways are generally available (according to Fig. 8): the condensation process 
involving pyrrole and various aldehydes, reaction mixture involved also in MW assisted 
procedures, the combination of substituted pyrroles carrying the desired future porphyrin 
substituents or via bilane structure; this last option was successfully applied on ABCD 
substituted porphyrins via synthesis of a protected acylbilane (by acid-catalyzed condensation 
of a acyldipyrromethane and protected dipyrromethane-n-carbinol) (Dogutan et al., 2007) and 
insertion of the substituents in meso positions in the already formed porphyrin core.  
The unsymmetrical porphyrins were chosen as our main synthetic target (Boscencu, 2008, 
2009, 2010; Oliveira, 2009) because 
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a. they are easy to prepare either via the Adler route (Adler et al., 1976) or by microvawe 
(MW) irradiation 
b. the phenolic hydroxy group is a suitable site on which to build a different substituent 
(Milgrom LR, 1983) 
c. the 4-methoxycarbonyl side-chains of the other meso-substituents may be de-esterified 
to convert a hydrophobic porphyrin into a hydrophilic one.  
3.4.2 Synthesis by microwave irradiation  
Microwave-assisted procedure is now a valid method to synthesize various type of 
compounds, including porphyrins and related structures, with significant advantages, from 
eco-friendliness to fastness and selectivity (Loupi et al., 2001). Since the first successful 
attempt for the meso-5,10,15,20 tetraphenylporphyrin (Petit et al., 1992), a wide range of 
compounds were obtained using either professional or domestic microwave ovens. The 
metalloporphyrins can also be obtained via MW methods (Mark  et al., 2005).  
Microwave-assisted procedures have become increasingly important in chemical synthesis 
in the last two decades due to several already proved important advantages over 
conventional heating pathways (table 4). 
The position of the microwave irradiation stage in preliminary evaluation- synthetic process-
purification- analysis chain is just by replacing classical Rothemund method with no 
additional operations (Fig. 9.) 
 
 
 
Fig. 9. Synthesis strategy for obtaining porphyrinic compounds including both classical and 
MW irradiation methods 
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The microwave-assisted cyclocondensation of benzaldehyde and pyrrole in dry media or in 
propionic acid  (Chauhan  et al., 2001) produces  5,10,15,20-tetraaryl porphyrins type with 
excellent yields. 
 
Characteristics Classical Method MW Method 
Reaction environment 
(starting materials) 
Complex 
(reactants in greater number) 
Simple 
Conditions 
Difficult 
(pressure, temperature, Nitrogen 
atmosphere) 
Easy 
Experimental 
Precautions 
(adding reagents under special 
conditions) 
No restrictions 
Reaction yield Small-Average Average-High 
Time Hours-Days Minutes 
Toxicity Average Average-Low 
Secondary 
reaction products 
High 
(separation in several steps) 
Few 
(easier separation) 
Chlorine 
(related structure) 
Present Absent 
Table 4. Characteristics of the MW vs. classical synthetic method 
The pathway towards improved photosensitizers imposed extended interdisciplinary 
studies. The second generation of photosensitizers will provide a large volume of “starting 
material” for future clinical tests, considering that the present synthetic methods can 
provide almost all types of substituted porphyrinoid systems.  
4. Other medical applications of porphyrins 
Porphyrins and metalloporphyrins have applications in cancer therapy, in photodiagnosis 
and more recently in chronic pain management and in the emerging field called theranostics 
which is actually a combination between therapy and diagnosis (Ray et al., 2010).  
4.1 Cancer therapy 
4.1.1 Boron neutron capture therapy 
Boron neutron capture therapy (BNCT) is a binary radiation therapy approach, bringing 
together two components which, when kept separate, have only minor effects on cells. The 
first component is a stable isotope of boron (boron-10) that can be concentrated in tumor 
cells by attaching it to tumor-seeking compounds. The second is a beam of low-energy 
neutrons. Boron-10 into or adjacent to the tumor cells disintegrates after capturing a neutron 
producing high energy heavy charged particles which destroy only the cells in close 
proximity, primarily cancer cells, leaving adjacent normal cells largely unaffected. Clinical 
interest in BNCT has focused primarily on the treatment of high-grade gliomas and either 
cutaneous primaries or cerebral metastases of melanoma, most recently, head, neck and 
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liver cancer. Neutron sources for BNCT are limited to nuclear reactors and these are 
available in the US, Japan, several European countries, and Argentina (Bregadze et al., 2001; 
Evstigneeva et al., 2003; Fronczek et al., 2005; Ol’shevskaya et al., 2006; Vicente et al., 2003). 
Boron-containing porphyrins have excellent tumor-localizing properties (Vicente, 2001) and 
have been proposed for dual application as boron delivery agents and photosensitizers for 
PDT in brain tumors (Rosenthal, 2003). 
4.1.2 Anticancer drugs 
A series of interesting gold(III) meso-tetraarylporphyrin complexes with relevant 
antiproliferative effects on CNE1 human cancer cell lines were described by Che et al. 
(2003).  Among them, the complex Au(III)(p-H-TPP)]Cl was found to be more cytotoxic for 
CNE1 than cisplatin. The lack of cross-resistance suggested that gold(III) porphyrins and 
cisplatin induced cytotoxicity through different mechanisms. Replacement of Au(III) with 
Zn(II) drastically reduced the drug potency. 
Cationic Mn porphyrins may be advantageous compared to other anti-cancer drugs, owing 
to their ability to afford pain management in cancer patients (Rabbani et al., 2009).  
4.1.3 Carriers for anti-cancer drugs 
The tumor-affinity of porphyrins has been exploited for designing porphyrin–anticancer 
drug conjugates. Brunner et al. created a series of porphyrin–platinum conjugates by 
combining porphyrin with cytotoxic platinum complexes (Brunner, 2004; Lottner, 2002). 
Zhou reported some porphyrin – DNA-alkylation-agent conjugates (Zhou, 2006) and Guo et 
al. (2003, 2004) prepared conjugates by linking porphyrin with other nitrogen heterocyclic 
species. However none of the conjugates mentioned above may be considered as a prodrug, 
since they do not release the actual drug. The first example of a porphyrin anticancer 
prodrug was reported in 2008 and consists of three parts: a porphyrin, a photocleavable o-
nitrobenzyl moiety as a light-triggered group, and a parent anticancer drug Tegafur (Lin et 
al., 2008). The prodrug is significantly less toxic than its parent anticancer drug Tegafur, 
which is released upon photoactivation. 
Combined with the up-to-date medical fiber optic technique, the light-triggered 
porphyrin anticancer prodrugs may find useful applications in chemotherapy to minimize 
side effects of anticancer drugs and in the light-controllable anticancer drug dosing 
(McCoy et al., 2007). 
4.2 Chronic pain management 
Severe pain syndromes reduce the quality of life of patients with inflammatory and 
neoplastic diseases, partly because reduced analgesic effectiveness of chronic opiate therapy 
leads to escalating doses and distressing side effects. Peroxynitrite (ONOO−) and its reactive 
oxygen precursor superoxide (O2−), are critically important in the development of pain.  
Metalloporphyrins have the highest rate constants for scavenging O2− and ONOO− and 
were shown to alleviate conditions originating from oxidative stress, such as diabetes, 
cancer, radiation injury, and central nervous system injuries, including morphine 
antinociceptive tolerance (Salvemini & Neuman, 2010, Salvemini et al., 2011). The most 
potent ONOO− scavengers and superoxide dismutase mimics reported so far are cationic 
Mn(III) N-alkylpyridylporphyrins (Fig. 10) (Batinić-Haberle et al, 1999; Rebouças et al., 
2008a; Rebouças et al., 2008b).  
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Fig. 10. Metalloporphyrins reported as radical scavengers 
4.3 Photodiagnosis 
The intriguing “tumor-localization” nature of porphyrins prompted the development of 
porphyrin-based diagnostic pharmaceuticals for different imaging modalities (Lipson, 1961; 
Nelson, 1991) or radioactive tracers (Nakajima et al., 1993) for tumor detection with 
encouraging results (Lee et al., 2010).  
4.3.1 Contrast media for MRI 
Magnetic resonance imaging (MRI) with molecular probes offers the potential to monitor 
physiological parameters with high spatial and temporal resolution, but the construction of 
cell-permeable imaging agents remains a challenge. Membrane permeability, optical 
activity, and high relaxivity of porphyrin-based contrast agents offer exceptional 
functionality for in-vivo imaging. It was recently shown that a porphyrin-based MRI 
molecular imaging agent, Mn-(DPA-C2)2-TPPS3, effectively penetrates cells and persistently 
stains living brain tissue in intracranially injected rats. Due to cromogenicity, its distribution 
can also be observed by histology (Chen, 1984; Lee, 2010; Shahbazi-Gahrouei, 2001).  
Porphyrin-based complexes were also identified as necrosis-avid contrast agents (NACAs) 
for noninvasive MRI identification of acute myocardial infarction, assessment of tissue or 
organ viability, and therapeutic evaluation after interventional therapies (Ni, 2008). 
4.3.2 NIR fluorescent probes 
The NIR region of the spectrum offers considerable opportunities for diagnosis because of 
the lack of interference with endogenous absorbers such as haeme pigments and melanin. In 
this region, light is able to penetrate deeper into tissue, thus offering routes to the therapy of 
blood vessel disorders and larger or deeper seated malignancies.  
Although the greatest activity in the synthesis of NIR-absorbing compounds for therapeutic 
intent has come from the porphyrin area, with bacteriochlorins and texaphyrins being 
promising derivatives, none of them is yet in everyday use (Wainwright M., 2010). 
5. Current limitations and future trends  
Only a small part of the impressive number of synthesized porphyrinic compounds is 
highly efficient in PDT, so the quest for the ideal photosensitizer still continues. 
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5.1 Coupling with light sources 
Several porphyrin related photosensitizers are currently on the market. Unfortunately, they 
have several limitations. The perfect balance and fulfilment of the criteria displayed in Table 
1, is not reached at this stage of development. The light sources, especially lasers, are 
increasingly acquiring improved characteristics, so more and more photosynthetizers can be 
used in biomedical applications and consequently an increased number of tumors are 
targeted. Future developments in porphyrinic-type photosensitizers will be oriented toward 
interdisciplinary applications. The improvement of lasers, mainly with increased tissue 
penetrability, will be associated with the significant development of new photosensitizers, 
not necessarily related to porphyrins.  
5.2 Dosimetry of PDT 
Despite promising in vitro studies, many attempts to use PDT in the clinic have led to 
inadequate tumor response or unacceptable side-effects, and this is partially due to the 
complexity of PDT mechanisms and the associated dosimetry problems. We must take into 
account that the local concentration of photosensitizer varies within the body and inter-
individual variability is registered. The penetration of light into the target depends on the 
specific optical properties of particular tissues. If the tissue is hypoxic, or becomes hypoxic 
due to PDT, the yield of singlet oxygen will be lower than expected. Therefore, development 
of accurate modeling tools, definition of PDT “dose” and in vivo measurements are 
nowadays major challenges in PDT.  
5.3 Oxygen and singlet oxygen 
Target tissue oxygenation is one of the essential factors coupled with the photosensitizers 
behavior (Patterson M.S. & Mazurek E., 2010; Ogilby P.R., 2010; Wilson et al., 2007). Oxygen 
can be measured invasively using implanted oxygen electrodes. But, as demonstrated in 
radiotherapy studies, the spatial distribution can be highly non-uniform. Non-invasive 
methods based on magnetic resonance or optical absorption spectroscopy can provide 
indirect measures of oxygen concentration, and were associated with porphyrins and 
related structures (Yu et al., 2005). 
Singlet oxygen remains at the cutting-edge of modern science, particularly in 
photosensitised systems. Singlet oxygen brings together seemingly disparate issues such as 
nanoparticle-dependent surface plasmon resonances and genetically engineered protein 
tagging experiments.  
The conventional method used for direct singlet oxygen measurement is the detection of the 
weak phosphorescence emitted at 1270 nm when singlet oxygen returns to the ground state. 
Upon laser excitation the singlet oxygen emission decay is detected at a 90º geometry with a 
germanium photodiode working at room temperature. Luminescence intensity at a time, t, 
after laser pulse is measured for the compound under study and for a reference compound 
with known singlet oxygen quantum yield on the desired solvent and matched optical 
density. Accurate calibration curves, with linear dependence of singlet oxygen emission 
intensity versus laser energy are obtained and a comparison of the slopes for the sample and 
those of the reference yields the singlet oxygen quantum yield. (Oliveira A.S. et al. 2009 and 
Santos P.F. et al. 2003, 2004, 2005). Nowadays it is already possible to “see” the spectra of 
singlet oxygen emission in the NIR region using a cooled IndiumGaliumArseniate (InGaAs) 
Carged Coupled Device (CCD) detector in the arrangement above described (Oliveira A.S. 
et al. 2011). 
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The cumulative singlet oxygen signal measured during PDT of cell suspensions correlated 
well with cell survival over a range of treatment conditions. Unfortunately, local concentration 
of singlet oxygen is in the picomolar range due to its rapid reaction with biomolecules 
(emission of only about 108 photons cm-3 s-1) and the biological microenvironment might 
influence the real 1270 nm emission. Accordingly, the instrumentation for detecting such weak 
luminescence is relatively complex and expensive. Lately, an effective method, Singlet Oxygen 
Luminescence Dosimetry (SOLD) for quantitative PDT related photobiological studies was 
evaluated and considered as optimal tool to evaluate photosensitizers in correlation with 
delivery methods (Jarvi et al., 2006). 
The group of Zhang (2008) increased the generation of singlet oxygen via electric-field metal–
photosensitizer interactions, taking advantage of near-field interactions of fluorophores with 
metallic nanoparticles, a phenomenon called metal-enhanced fluorescence (MEF). Nonradiative 
energy transfer occurs from excited distal fluorophores to the surface plasmon electrons on 
noncontinuous films. The surface plasmons in turn radiate the photophysical characteristics of 
the coupling fluorophores. However, additional work is required to optimize or control the 
amount of singlet oxygen generation from photosensitizers in proximity to metal nanoparticles. 
Molecular Probes (Invitrogen Inc.) developed the Singlet Oxygen Sensor Green reagent, 
which is highly selective for singlet oxygen. It exhibits initially weak blue fluorescence, with 
excitation peaks at 372 and 393 nm and emission peaks at 395 and 416 nm. In the presence of 
singlet oxygen, it emits a green fluorescence similar to that of fluorescein (excitation/ 
emission maxima ~504/525 nm). Unfortunately, the reagent has only in vitro applications 
and is used only for cumulative measurements.  
Price et al (2009) showed that 3′-p- (aminophenyl) fluorescein (APF) is adequate for the 
detection of singlet oxygen and hydroxyl radical  under conditions relevant to PDT, in cell-free 
studies and in cultured L1210 cells photosensitized with benzoporphyhrin. Studies have to be 
performed in the presence and absence of DMSO to eliminate hydroxyl radical contribution.  
The group of Lee S (2010) developed two instruments, an ultra-sensitive singlet oxygen 
point sensor and a 2D imager, as real-time dosimeters for PDT researchers. The 2D imaging 
system can visualize in vitro and in vivo spatial maps of both the singlet oxygen production 
and the localization of the photosensitizer in a tumor during PDT. 
5.4 Photosensitizer delivery 
Penetration of the photosensitizer into tissues is the major limiting factor in PDT. Porphyrin-
like molecules are polycyclic, often heavily charged and in many cases insoluble in both 
hydrophilic and lipophilic media. In addition, porphyrins and their analogues are known to 
self-aggregate, which is facilitated by a flat, wide, and electron-rich surface, creating van der 
Waals, π–π stacking, charge-transfer interactions (Andrade et al., 2008). Therefore, finding 
adequate drug delivery systems is crucial in improving bioavailability, target specificity and 
cellular localization of photosensitizers in PDT. Drug targeting from parenteral 
administration of photosensitizers has been achieved by using liposomes, oil emulsions, 
microspheres, micellar nanoparticles, proteins and monoclonal antibodies, but the ideal 
formulation has not yet been developed.  
Polymeric nanoparticles offer numerous advantages over the conventional drug delivery 
systems including high drug loading, controlled release, and a large variety of carrier 
materials and pharmaceutical formulations (Konan, 2002).  
In the development of new drug delivery principles and devices, one may take advantage of 
the very basics of PDT, namely photoactivation. The method provides a broad range of 
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adjustable parameters (e.g., wavelength, intensity, duration, spatial and temporal control) that 
can be optimized to suit a given application. Photoactivated drug delivery can be used to 
control the release rate of the active principle from a dosage form (i.e., a carrier system), to 
activate a drug molecule that is already present at the site of action in an inactive form (e.g., a 
photosensitizer or a prodrug), or it can combine the two (i.e., photocontrolled drug release and 
drug activation). While photoactivation of sensitizers is well established, the application of 
photoactivated carrier systems offers new opportunities, including photoresponsive 
hydrogels, microcapsules, liposomes, nanoparticles and oligonucleotides (Sortino, 2008).  
As shown recently by Kishwar et al. (2010), ZnO nanorods proved to be an efficient light 
system attached to a photosensitizer for intracellular necrosis. Zinc oxide (ZnO) has many 
advantageous properties like direct band gap of 3.37 eV, large exciton binding energy of 60 eV 
at room temperature and deep level defects emissions that cover the whole visible range. The 
UV and green emission part of the white light of ZnO can be used for the activation of 
photosensitizers in PDT. The family of ZnO nanostructures is the richest known so far and the 
growth of these nanostructures is facilitated by the self organized growth property of this 
material. Being a bio-safe and bio-compatible material, ZnO is an attractive candidate for 
biomedical applications. ZnO nanorods grown on the femto tip were shown to deliver the 
photosensitizer to breast cancerous cells and cause necrosis within few minutes. Topical pain 
caused by the conventional PDT method can be reduced by this technique.  
5.5 Increased fluorescence for photodiagnosis 
There is a tremendous need for developing novel non-invasive or minimally invasive 
diagnostic tools for assessing cell/tissue metabolism and functions, in order to discriminate 
pathological disturbances in early disease stages. The capability to visualize pathologic tissues 
as first step before surgical procedure or therapy, may clearly increase treatment efficacy.  
Intensive research is done to get probes with appropriate fluorescence characteristics (high  
quantum yield, large Stokes shifts, reduced photolability and great suitability for cells and 
tissues, i.e., well-balanced amphiphyllic character, low or no intrinsic toxicity, higher excitation 
wavelengths to prevent spectral interferences due to the auto fluorescence of the biological 
samples). Due to the adequacy of their properties, the use of porphyrins and 
metalloporphyrins as near infrared probes (NIR probes) in biomedical applications increased 
exponentially. Porphyrinic structures, either in solution or in restricted nanometric geometries, 
typically display long decay times, and this can be used as an extra discrimination advantage 
for fluorescence imaging (long lifetime probes for lifetime based sensing). We believe that 
nowadays the analysis of porphyrins and porphyrin-like structures from the point of view of 
their fluorescence properties is crucial for developing minimally invasive fluorescent tools for 
diagnosis. 
Several studies on fluorescent photosensitizers show them as markers and beacons and point 
toward their dual utility for "seeing and treating" (Chen et al., 2005; Cló et al., 2007). Theranostic 
nanomedicine, integrating  nano-platforms which can diagnose, deliver targeted therapy and 
monitor response to therapy, is best illustrated in PDT. Photosensitizers will not only kill 
pathologic cells when light-activated, but being inherently fluorescent they can be used for 
imaging and locating disease as photosensitizers selectively accumulate within diseased tissue. 
The use of lasers and minimally invasive fiber optic tools, along with the development of new 
agents that respond to NIR wavelengths for better tissue penetration, makes direct targeting of 
deep tissues possible, enabling imaging and treatment of several pathologies. Alongside, 
nanoprobes have been developed for in vivo optical imaging, which include quantum dots, 
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up-converting nanophosphors, gold and silica nanoparticles, and photosensitizers containing 
nanoparticulate carriers. This approach is becoming of increasing interest for oncological 
applications, addressing the challenges of cancer heterogeneity and adaptability.  
5.6 Nano PDT 
The general advances in medicine and the progress in the use of photosensitizers for PDT 
directed the research towards the development of photoactive nanoparticles which can be 
used for cancer therapy, as sensors for tumor indication and imaging and for other 
applications of PDT such as vascular disorders (Paszko et al., 2011). The effectiveness of 
PDT could be maximised by using nanoparticles which can improve the photosensitizer 
solubility in aqueous media, its formulation properties and selectivity to the target tissue. 
Selectivity improvement can be achieved by nano-formulating the photosensitizers with 
liposomes or by modifying them using dendrimers, nanotubes (Zhu, 2008) or fullerenes;  
such liposomal formulation of Foscan (Foslip) is  currently under investigation (Buchholz, 
cited by  Lassale et al., 2008). 
6. Conclusions 
Porphyrins have a well-defined place among the substances used in biomedical engineering 
as medical devices (as defined by the European Council directives No. 93/42/EEC and  
98/79/EC, completed by the associated MEDDEV guidance documents) as they can be used 
effectively as both diagnosis and treatment tools.  
 
No Target 
Drug/Procedure/
Device
Theme Status 
1. Colorectal Cancer Optical Fluoroscopy Colorectal Cancer Detection by Means of Optical Fluoroscopy
Recruiting 2. 
Porphyria Cutanea 
Tarda 
Exjade Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
3. Glioma 5-Aminolevuline Acid
Safety Study of Aminolevulinic Acid (ALA) to 
Enhance Visualization and Resection of Malignant 
Tumors of the Brain
4 Lung Cancer CyPath 
Sputum Labeling Utilizing Synthetic Meso Tetra (4-
Carboxyphenyl) Porphine (TCPP) for Detection of 
Lung Cancer
Active 
5. Acne Vulgaris Visonac Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Completed 
6. Basal Cell 
Carcinoma 
PDT with Metvix 160 
mg/g cream 
PDT with placebo 
cream
Photodynamic Therapy (PDT) With Metvix Cream 
160 mg/g Versus PDT With Placebo Cream in 
Patients With Primary Nodular Basal Cell 
Carcinoma
7. Basal Cell 
Carcinoma 
PDT with Metvix
160 mg/g cream and 
Placebo cream
PDT With Metvix 160 mg/g Cream Versus PDT 
With Placebo Cream in Patients With Primary 
Nodular Basal Call Carcinoma
8. Porphyria Heme arginate;Tin mesoporphyrin
Phase I/II Study of Heme Arginate and Tin 
Mesoporphyrin for Acute Porphyria
9. Healthy Subjects Eltrombopag; Ciprofloxacin; Placebo
Study In Healthy Subjects To Evaluate The Photo-
Irritant Potential Of Eltrombopag
10. Basal Cell 
Carcinoma 
Procedure: PDT with 
Metvix 160 mg/g 
cream
Metvix PDT in Patients With "High Risk" Basal Cell 
Carcinoma 
11. Porphyria Heme arginate;Tin mesoporphyrin
Studies in Porphyria III: Heme and Tin 
Mesoporphyrin in Acute Porphyrias
Table 5. Current status of medical trials involving porphyrins (source: ClinicalTrials.gov) 
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To underline the importance of porphyrinic compounds and to reveal again their multivalency 
toward biomedical applications we present the current status (2011, April) of their involvement 
in a wide range of medical trials of the U.S. National Institutes of Health (see Table 5). 
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